Gene editing takes centre stage in FDA’s new rare disease approval pathway
The aim of the pathway is to remove red tape for bespoke therapies designed for patients with rare diseases.
Explore our marketing solutions
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
